LCC [Liverpool ChiroChem]

LCC [Liverpool ChiroChem] is a biotechnology startup leveraging its proprietary chiral chemistry platform to advance small molecule lead candidate assets for the treatment of oncology and rare diseases. Established in 2014, LCC has successfully developed its PACE platform, focusing on component quality and designed to encompass increased 3D-character and assured chiral purity, leading to enhanced novelty and diversity in chemical space. Through its £2.00M Venture Round investment on 14 April 2021 led by NPIF Maven Equity Finance, LCC has further strengthened its position in the market. The company's Chemistry Hub, which houses an ultra-large virtual chemical library containing innovative lead and drug-like compounds, has the potential for diverse applications in different therapeutic areas. For more information, visit their website at http://www.liverpoolchirochem.com/ or contact them at [email protected].